H
Hvivo
OrganizationHeard in 3 episodes across 2 shows since May 2026
A specialist clinical-services company conducting human challenge trials and related research for vaccines, antivirals, and infectious-disease treatments.
Episodes
3
across 2 shows
First heard
May 2026
Expert statements
1
1 positive
Episodes per month
Public PodLume episodes featuring it, over the last year.
1
2
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 1 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 2 |
| Sep 2026 | 0 |
| Oct 2026 | 0 |
| Nov 2026 | 0 |
Email alert
Email me when Hvivo comes up on a podcast
One email a week at most, with the new episodes that mention Hvivo. Free, no account needed, unsubscribe in one click.
What experts have said about Hvivo
1 statement · 1 positive
Hvivo is viewed favorably as an investment.
“we do like that one”
Open the episode · Paul's Podcast - Fri 8 May 2026Listen at 16:32
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
3 episodes featuring Hvivo, newest first
- Aug 25, 2026
European Green Transition targets rapid wind-services growthThe Sunday RoastAug 25, 2026 - Aug 2, 2026
Mining deals and biotech catalysts shape a midsummer market reviewThe Sunday RoastAug 2, 2026 - May 8, 2026
Paul Scott revisits a disputed Novacyte market moveUK Small/Mid Caps with Paul ScottMay 8, 2026